Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction

Summary: Recent studies send an unambiguous signal that the class of agents known as sodium-glucose–linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of...

Full description

Bibliographic Details
Main Authors: Kim A. Connelly, MBBS, PhD, Yanling Zhang, MD, Aylin Visram, BSc, Andrew Advani, BSc, MBChB, PhD, Sri N. Batchu, PhD, Jean-François Desjardins, MSc, Kerri Thai, BSc, Richard E. Gilbert, MBBS, PhD
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X18302985

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X18302985

Similar Items